Table 2.

Impact of clinical patients and disease characteristics on PET Choline results.

	PET-positive (n=161) N or median % or IQR		PET-positive + SBRT (n=73) N or median % or IQR		p-value
Age at diagnosis	66	(62-69)	66	(62-70)	0,153
PSA at diagnosis	10	(6.7-17.7)	9,8	(7-19)	0,920
Gleason at diagnosis
≤6 (low risk)	13	8,1%	4	5,5%
4+3 (intermediate risk, favourable)	26	16,1%	13	17,8%
3+4 (intermediate risk, unfavourable)	52	32,3%	19	26,0%
≥8 (high risk)	70	43,5%	37	50,7%	0,133
Hormone therapy (initial)
no	131	81,4%	58	79,5%
yes	30	18,6%	15	20,5%	0,210
PSA post-surgery	0,6	(0.0-0.71)	0,02	(0.0-0.5)	0,123
Adjuvant radiotherapy
no	133	82,6%	44	60,3%
yes	28	17,4%	29	39,7%	0,001*
PSA at recurrence	1,69	(1.00-3.81)	1,22	(0.69-2.43)	<0.001*
Recurrence (% yes)
lumbar nodes	6	3,8%	4	5,5%	0,015*
pelvic nodes	43	26,9%	46	63,0%	<0.001*
bone	33	20,6%	16	21,9%	<0.001*
lung	1	0,6%	0	0,0%	0,461
prostate	97	60,6%	13	17,8%	<0.001*
N positive sites at PET
0	0	0,0%	0	0,0%
1-3	150	93,2%	73	100,0%
>3	11	6,8%	0	0,0%	<0.001*
Hormone therapy (at recurrence)
no	68	42,8%	38	52,8%
yes	91	57,2%	34	47,2%	0,309
Chemotherapy (at recurrence)
no	148	93,1%	71	98,6%
yes	11	6,9%	1	1,4%	0,120

(*) significant results.